Has Precision Medicine Become Mainstream in Oncology?

Posted by Pavankumar Anne on Jun 28, 2019 8:00:00 AM

The promise of precision medicine—tailoring treatments to genetic changes in each cancer patient—is very exciting. Advances in science and genomic testing have helped speed up the pace of precision medicine and brought several innovative targeted therapies and immunotherapies to market already. Precision medicine was the theme at last year’s American Society of Clinical Oncology (ASCO) annual meeting, with more than 500 abstracts involving genomic testing. It’s safe to say that precision medicine has become a buzzy topic. However, at this year’s ASCO event, we continued to hear that there are significant challenges to the widespread adoption of precision medicine. What will it take to bring the promise of precision medicine to more patients and embed it in routine care?


>
Read More

Precision Medicine Comes Into View With the Use of Next-Generation Sequencing

Posted by Jon Roffman on Jun 27, 2018 8:00:00 AM

Marie Yurkovich and Olivia Tang-Kong co-authored this post with Jon Roffman.

Precision medicine in cancer care has been anticipated and talked about for years. The ability to classify a patient based on her tumor’s molecular changes and then treat her with the right targeted therapy is a concept that gives hope to the many men, women and children diagnosed with cancer. Given recent advancements, there’s good reason for this hope.


>
Read More

Multiple Myeloma at ASH 2017: Observations and Analysis

Posted by Josh Hattem on Dec 14, 2017 9:11:58 AM

There were 935 abstracts related to multiple myeloma accepted into the 2017 American Society of Hematology (ASH) Annual Meeting, or roughly one piece of new research for every 127 multiple myeloma patients in the U.S., according to the National Cancer Institute.


>
Read More